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BALB/c  mice  immunized  with  bacterial  levan  (BL),  a  /3(2---*6)  fructosan  with 
fl(2--*l)  branched points, produce antibodies of two general  types (1). One group of 
molecules is specific for inulin, which is a fl(2---* 1) fructosan, as well as for levan; such 
antibodies,  which can  first  be detected  in  BALB/c mice at  28 d  of age  (2), express 
idiotypes  (Id)  that cross-react with  those found on inulin-binding  myeloma proteins 
(3). The second principal  group of antibodies  binds  BL, but  not  inulin,  and  fails to 
express cross-reactive idiotypes (IdX) of anti-inulin antibodies (1); these can be elicited 
in  l-d-old BALB/c mice after immunization with BL (2).  The Id found on myeloma 
proteins ABPC 48 (A48) and  UPC  10  (UI0), which bind BL but  fail to bind inulin, 
are  generally  not  detected  on anti-BL antibodies  of BALB/c mice  (3).  However,  in 
nu/nu  BALB/c mice,  pretreatment  with  anti-El09  IdX antibodies  before  immuni- 
zation  with  BL  results  in  the  occurrence  of A48  Id  +  anti-BL  antibodies  (4).  This 
observation indicates that the A48 Id  ÷ anti-BL response belongs to a  normally silent 
fraction  of the  anti-BL  repertoire.  This observation  prompted  us  to investigate  the 
activation of A48 Id+-bearing clones in neonates after the administration  of anti-A48 
Id antibodies.  Our results indicate that  the administration  of anti-A48 Id antibodies 
to  1-d-old BALB/c mice causes a  substantial  increase  in  the A48 Id  ÷ component  of 
the anti-BL antibody response. 
Materials  and Methods 
Animals.  1-d-old  BALB/c mice were purchased from the Charles River Breeding Labora- 
tory, Wilmington, Mass. 
Antigen.  BL was  isolated  by  alcohol  precipitation  from  culture  supernates  of Aerobacter 
laevenicum (ATCC  15552) grown at  23°C in nutrient  broth supplemented with 5-10% sucrose. 
Trinitrophenyl-aminoethylcarbamylmethyl-Ficoll (TNP-Ficoll) was prepared as described pre- 
viously (5). 
Myeloma Proteins.  The BALB/c myeloma proteins used in this study were A48, MOPC 460 
(M460),  and  MOPC  384  (M384);  all  are  IgA,x  immunoglobulins.  A48  possesses  fl(2---.6) 
fructosan-binding activity and  lacks  the  IdX of myeloma proteins  that  bind  both  BL and 
inulin.  M460 is a TNP-binding myeloma protein, whereas M384 possesses Salmonella tranaroa 
lipopolysaccharide-binding  activity.  These  myeloma  proteins  were  kindly  provided  by  Dr. 
Michael Potter, National Cancer Institute, National Institutes of Health, Bethesda, Md. 
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Preparation of Anti-ld Antibody.  Anti-A48 Id (Abe) antisera were prepared in BALB/c mice by 
immunization with  an  A48-keyhole limpet  hemocyanin conjugate.  Anti-M460 Id and  anti- 
M384  [d antisera were prepared in  the same way. The method used for coupling myeloma 
proteins to keyhole limpet hemocyanin, as well as the schedules employed for immunization, 
have been described elsewhere (6). 
Sensitization of Sheep Elythrocytes (SRBC) with BL and TNP.  A palmitoyl derivative of levan 
was  prepared  by  the  method  of Tsumita  and  Ohashi  (7)  as  modified  by  Leon  et  al.  (8). 
However, we used 50 #1 instead of 25 #l of palmitoyl chloride to make the derivative, which was 
lyophilized  and stored in the dry state. Before use, the palmitoyl-BL was dissolved in phosphate- 
buffered saline (pH  7.4) at a concentration of 1 mg/ml; then SRBG were incubated with an 
optimal quantity of the solution of palmitoyl-BL (25 #1) at 37°G for I h. TNP-sensitized SRBC 
were prepared by the method of Rittenberg and Pratt (9). 
Detection of Plaque-forming Cells (PFC).  The number of cells secreting antibody specific for 
BL or TNP  was determined by a  slide version of the technique of localized hemolysis-in-gel 
(10).  Here, 50 #1 of a suspension of immune spleen cells was added to 0.4 ml of 0.6%  agarose 
that contained 0.2 ml of sensitized erythrocytes. The slides were incubated for 2 h at 37°C and 
then  in  the  presence of guinea  pig complement  (1:20)  for an  additional  I  h.  For cqntrols, 
additional slides were prepared using a mixture of the same immune spleen cells and unsensi- 
tized SRBC. Anti-BL PFC carrying the A48 Id were estimated by the addition to agarose of 
BALB/c anti-A48 antiserum at a  final dilution of 1:100 and then by subtracting the number 
of PFC obtained from the number of those observed when no inhibitor (anti-A48) was present. 
Similarly, the  number  of anti-TNP  PFC  expressing the  M460  Id  was  determined  by  the 
addition to agarose of BALB/c anti-M460 antiserum (1:100)  as inhibitor. 
Radioimmunoassay.  Purified Ab2  (anti-A48  Id)  antibodies were  tritiated according to  the 
method of Wilder et al. (11).  Mierotiter plates were coated with 50 #1 of a 30 #g/ml solution of 
A48 Id  ÷ antibodies for  18 h at 4°C. Then  the plates were washed three times with saline and 
incubated for 1 h with 50% fetal calfserum in saline at 4°C. Thereafter, the plates were washed 
three times with saline and used for inhibition by incubation of 3H-Ab2 antibodies (5,000 cpm/ 
50 #1) with various dilutions of inhibitory sera for 3 h at 4°C. These plates were then washed 
extensively and the radioactivity was measured in a  liquid-scintillation spectrometer. 
Statistics.  The  Student's  t  test  was  used  to  evaluate  the  significance of the  differences 
observed. Differences were considered to be significant when probability (P) values <0.05 were 
obtained. 
Results 
The  anti-BL  PFC  response  was  studied  in  l-mo-old  BALB/c  mice  which  were 
pretreated after  birth  (i.e., at  1 d  of age)  with  various amounts  of affinity-purified 
BALB/c anti-A48 Id antibody. As can be noted from the data of Table I, pretreatment 
with 0.01-10 #g of antibody leads to the activation of A48 Id  + clones after immuni- 
zation with BL; the percentage of A48 Id  + PFC detected was significantly larger than 
that  found  in  mice  not  treated  with  anti-A48  Id  antibody  (P  <0.05).  Moreover, 
pretreatment  with 0.1-10 #g of antibody induces a  significant overall suppression of 
the  anti-BL  PFC  response.  Because  there  is  a  substantial  ontogenic  delay  in  the 
expression of the IdX + anti-inulin response, which is expressed maximally at 4-6 wk, 
we also studied the activation of A48 Id  + clone in 7-wk-old mice. The data presented 
in Table II indicate that pretreatment with 0.01 #g of affinity-purified BALB/c anti- 
A48 Id antibody produces a  similar effect with  respect  to activation of the A48  Id  + 
clone in older mice, even though  the anti-BL response is higher in magnitude at  that 
age.  These  results  indicate  that  the  activation  of anti-inulin clone by  BL  does  not 
interfere with  the activation of the A48  Id  + clone.  In other experiments, we investi- 
gated the specificity of the activation of the A48 Id  + clone in neonatal mice pretreated 
with  anti-A48  Id  antibody.  The  data  of Table  III  show  that  pretreatment  with 
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TABLE  I 
Effect of Treating Newborn Mice with  Various Doses of Anti-A 48 Id 
Antibody on the Anti-BL PFC Response 
Dose of anti-A48  Id 
given*  BL-specific PFC/spleen~  A48 Id + PFC 
--  3.600 ±  0.125  (3,977)  6  :t: 3 
0.01  3.508 +  0.123  (3,218)  46 4-  14 
0.1  2,855  ±  0.218  17171  65 ±  17 
1.0  2.960 ±  0.127  (913)  73 ±  20 
10.0  2.999 +- 0.183  (997)  73 _+  I9 
* Mice were  1 d  old at  the time of treatment. 
:~ Mean :t: SEM for log,0 PFC/spleen detected  for 5 mice, 5 d  after i.v. immunization with 
20/xg BL;  the geometric mean is in parentheses.  Mice were 5 wk of age at  the time of 
immunization. 
TABLE  II 
Anti-BL Response of Mice Pretreated With 0.01 #g of Anti-A48 Id 
Antibody at 1 d of Age 
Age of mice when 
immunized with  BL-specific PFC/spleen*  A48 Id + PFC 
20 ~g BL 
wk  '~ 
4  3.431  ±  0.081  (2,700)  52 ±  7 
5  3.508 +_ 0.123  13,2181  46 +  14 
7  4.025  ±  11.121 110,5861  47 ±  9 
* Mean  4- SEM  for log~0 PFC/.spleen  detected  for 5  mice, 5  d  after immunization:  the 
geometric mean is in parentheses. 
TABLE  III 
Specificity of the Enhancement of the A48 Id  + Component of the Anti-BL Response by Anti-ld Antibody 
Mice primed with  BL-specific PFC/spleen*  A48 Id + PFC  A48 Id bearing molecules:~ 
' Z,  llg  / m l 
--  3.290 4- 0.110  (1,950)  6  4- 3  0.004  4- 0.64.)2 
0.01 /.tg anti-A48  Id  3.431  ±  0.081  (2,700)  52 +- 7  0.430  ±  0.162 
0.01 p.g anti-M384  Id  3.150  ±  0.043  (1,411)  3 +-  1  0.048 -+ 0.014 
* See footnote of Table II. Mice were 4 wk of age at the time of immunization with BL. 
:t: The results calculated  are based on the capacity of various concentrations  of A48 ld antibody  to inhibit the binding of 
3H-anti-A48  Id antibody  to  plates  coated  with A48 Id antibody  (30/ag/ml).  The results are expressed  as the mean  ± 
SEM for five mice. 
TABLE  IV 
Specificity of the Enhancing Effect of Anti-A48 Id Antibody on the Anti-BL PFC Response 
Mice primed with  Mice challenged  BL-specific PFC/  A48  A48 Id-bear-  TNP-specific PFC/  M460 
with  spleen*  Id +  ing molecules:~  spleen*  Id + 
%  ~g/ml  '/~ 
--  20 #g BL (i.v.)  3.290 ±  0.110  (1,950)  6  ±  3  0.004 ±  0.002  ND§  ND 
0.01 ~g anti-A48  ld  3.431  ±  0.081  (2,700)  52 ±  7  0.430 ±  0.162  ND  NI) 
--  20 #g TNP-Ficoll  1.280 _+ 0.171  (19)  ND  ND  4.590 4- 0.067  138,9191  16 ±  7 
(i,v.) 
0.01 /~g anti-A48  Id  1.309 4- 0.208  (20)  ND  0.002  ±  0.001  4.438  ±  0.206  (27,442)  24 -+ 6 
* See footnote of Table II. Mice were 4  wk of age at the time of immunization. 
:~ See footnote :[: of Table  III. 
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4  wk later,  does  not  lead  to  the  activation of the  A48  Id  + clone.  Furthermore,  in 
BALB/c mice pretreated with anti-A48 Id antibody and then immunized 1 mo later 
with TNP-Ficoll, we did not observe a significant increase in the anti-BL response nor 
a  significant  alteration  in  the M460  Id  ÷ component of the anti-TNP response  (see 
Table  IV).  It  can  be seen  in  Tables III and  IV  that  the  radioimmunoassay  data 
confirm the  PFC  results.  These experiments clearly indicate  that  the activation  of 
A48 Id  + clone by affinity-purified BALB/c anti-A48 Id antibody is a specific phenom- 
enon that requires antigenic stimulation for its expression. 
Discussion 
The  Id  expressed  on  the  fl(2---~6)  polyfructosan-binding  myeloma  protein  A48 
cannot be detected on anti-BL antibody produced by BALB/c mice, IgC~ congenic 
mice, or recombinant inbred strains of mice after immunization with BL (3). However, 
A48  Id  + anti-BL antibody can be detected  in  El09  IdX-suppressed nude  BALB/c 
mice, as well as in adult  BALB/c mice producing anti-(anti-A48 Id) antibody after 
immunization with BL (4,  12). This observation indicates that the A48 Id  + anti-BL 
response  belongs  to  a  normally  silent  fraction  of the  anti-BL  repertoire.  In  this 
communication, we present additional data that indicate that a substantial proportion 
of A48 Id  + anti-BL response can be activated after a single injection of 0.01-10 #g of 
affinity-purified BALB/c  anti-A48  Id antibody given near the  time of birth.  Such 
activation requires antigenic stimulation to be expressed, because no significant anti- 
BL PFC response was noted in  mice pretreated with anti-A48 Id antibody but  not 
immunized with BL. The effect produced by anti-A48 Id antibody is specific, because 
such  treatment  did  not  alter the  M460  Id  +  component  of anti-TNP  response and 
pretreatment with anti-M384 antibody did not lead to the activation of the A48 Id  + 
component of anti-BL response. Interestingly, neonatal pretreatment with 0.1-10 #g 
of antibody, which leads to a significant decrease in the magnitude of the total anti- 
BL  antibody  response,  also  activates  the  A48  Id  ÷  component.  These  data  are  in 
agreement with previous reports showing that small amounts of anti-Id antibody can 
prime  (in  adult  animals)  the  precursors of Id-bearing, antibody-forming cells  that 
belong to the expressible repertoire (13-15). 
Studies  now  in  progress  are  designed  to  investigate  the  cellular  basis  for  the 
activation of the A48 Id  + silent clone. However, the results of this work clearly indicate 
that low doses of anti-Id antibody preferentially and substantially activate precursors 
of  cells  capable  of  making  A48  Id  ÷  antibody;  this  clone  can  be  expanded  by 
immunization  with  BL of either  1-mo-old mice that  lack the  ability to  mount  an 
IdX  ÷  anti-inulin  response  or  of older  mice  that  are  able  to  make  an  anti-inulin 
antibody response after immunization with BL. 
Summary 
BALB/c mice immunized with bacterial levan (BL) produce an immune response 
that fails to generate antibody expressing the idiotype (Id) of the fl(2--.6)  fructosan- 
binding myeloma protein ABPC 48  (A48).  Pretreatment  of newborn  BALB/c mice 
(at  1 d  of age)  with  0.01-10  #g of affinity-purified  BALB/c  anti-A48  Id  antibody 
followed by immunization with BL  1-2 mo later produces an anti-BL response that 
expresses the A48 Id. This shows that A48 Id  + anti-BL clones belong to a  normally 
silent fraction of the anti-BL repertoire. The activation of A48 Id  + anti-BL clones by 1008  HIERNAUX  ET  AL.  BRIEF DEFINITIVE REPORT 
anti-A48 Id antibody is specific because the pretreatment of newborn mice with anti- 
MOPC  384  Id  antibody,  followed by  immunization  with  BL,  does  not  lead  to  its 
activation. Moreover, pretreatment of mice with anti-A48 Id antibody does not alter 
the MOPC  460 Id  + component of the anti-TNP response. It is also important to note 
that  the  activation  of the  A48  Id  +  clone  in  pretreated  mice  requires  subsequent 
immunization with BL. 
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